The Food and Drug Administration has granted approval for a new formulation of piflufolastat F 18 injection, marketed as Pylarify TruVu, designed to improve the detection of prostate cancer. This advancement builds upon the initial FDA approval of Pylarify in May 2021, offering a potentially more accessible and efficient diagnostic tool for men facing prostate cancer concerns.
Prostate cancer remains a significant health challenge, and accurate staging and monitoring are crucial for effective treatment. Pylarify TruVu utilizes positron emission tomography (PET) imaging to identify prostate-specific membrane antigen (PSMA) positive lesions, aiding in the detection of suspected metastasis or recurrence. The new formulation aims to address logistical hurdles associated with producing and distributing the imaging agent, ultimately expanding patient access to this key diagnostic technology.
Enhanced Production and Accessibility
Pylarify TruVu was developed through the 505(b)(2) regulatory pathway, allowing the FDA to consider data from two pivotal studies when evaluating its safety and efficacy. According to Lantheus Holdings, the manufacturer, the new formulation enhances product stability at higher radioactive concentrations. This improvement is expected to increase batch sizes and enable production at facilities equipped with high-energy cyclotrons, potentially reaching more patients across a wider geographic area.
“The FDA approval of Pylarify TruVu demonstrates Lantheus’ continued commitment to advancing innovation that directly expands patient access to high-quality diagnostic tools,” said Mary Anne Heino, executive chairperson and CEO of Lantheus Holdings, in a press release. “The availability of Pylarify TruVu addresses a key need identified by clinicians — greater access to our market-leading formulation.”
How Pylarify TruVu Works
The agent is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who are suspected of having metastasis and are candidates for initial definitive therapy, or who are suspected of recurrence based on elevated prostate-specific antigen (PSA) levels. PSMA is a protein found on the surface of prostate cancer cells, making it a valuable target for imaging. By binding to PSMA, Pylarify TruVu allows clinicians to visualize the location and extent of cancer within the body.
The original Pylarify formulation received FDA approval in 2021 for the same indications. The new formulation, Pylarify TruVu, is expected to offer similar safety and efficacy profiles, while streamlining the manufacturing process. This is particularly important as demand for PSMA PET imaging continues to grow.
Pylarify TruVu is anticipated to be commercially available in the fourth quarter of 2026. Clinicians and patients can expect increased availability of this important diagnostic tool as production capacity expands.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
This new formulation represents a step forward in prostate cancer diagnostics, potentially improving access and efficiency for patients and clinicians alike. Further research and clinical experience will continue to refine the use of Pylarify TruVu in managing this complex disease. Share your thoughts and experiences in the comments below.
